Semaglutide Users Abandon Breakthrough Weight-Loss Drug Within a Year

Most Quit Breakthrough Weight-Loss Drug Within a Year A massive Danish study has revealed that more than half of adults without diabetes who use the breakthrough weight-loss drug semaglutide quit within a year, citing high costs, unpleasant side effects, and underlying medical or psychiatric conditions as major reasons. The findings, presented at this year's Annual Meeting of The European Association for the Study of Diabetes (EASD), raise concerns about the long-term effectiveness of these medications. According to the study, conducted by researchers from the University of Copenhagen, 54% of users without diabetes stopped taking semaglutide within a year. Younger users and men were especially prone to quitting, with 64% of those under 40 and 62% of men discontinuing treatment. Discontinuation often led to weight regain, highlighting the need for more effective strategies to support long-term weight management. "We were surprised by the high dropout rate," said Dr. Trine Clausen, lead author of the study. "Our results suggest that while semaglutide is an effective medication for weight loss, it's not a magic bullet. We need to address the underlying issues that cause people to quit treatment." Semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1RA), has been hailed as a breakthrough in the fight against obesity. It works by mimicking a natural hormone that regulates appetite and glucose metabolism. However, its high cost – around $1,000 per month – and potential side effects, such as nausea and diarrhea, have raised concerns about accessibility and tolerability. The study's findings have significant implications for public health policy and healthcare systems worldwide. "This study highlights the need for more affordable and accessible weight-loss treatments," said Dr. Clausen. "We also need to develop more effective strategies to support patients in maintaining weight loss over time." In addition to the high dropout rate, the study found that underlying medical or psychiatric conditions played a significant role in discontinuation. Patients with depression, anxiety, or other mental health conditions were more likely to quit treatment. The European Association for the Study of Diabetes (EASD) has emphasized the importance of addressing these issues through multidisciplinary approaches, including behavioral therapy and lifestyle interventions. As researchers continue to explore new treatments for obesity, the study's findings serve as a reminder that effective weight management requires a comprehensive approach. "We need to move beyond just prescribing medications," said Dr. Clausen. "We need to address the complex interplay between physical and mental health, social determinants of health, and healthcare systems." The study's results have sparked renewed interest in developing more affordable and accessible weight-loss treatments. Pharmaceutical companies are exploring new formulations and delivery methods, while researchers are investigating alternative approaches, such as gene therapy. In conclusion, the Danish study highlights the challenges facing individuals seeking to lose weight with semaglutide. While the medication has shown remarkable efficacy, its limitations underscore the need for a more comprehensive approach to obesity treatment. As researchers continue to explore new solutions, they must prioritize accessibility, affordability, and patient-centered care. Background: Semaglutide was approved by regulatory agencies in 2021 as a treatment for type 2 diabetes and later expanded to include weight loss indications. GLP-1RAs have been shown to be effective in promoting weight loss and improving glycemic control. Additional Perspectives: "This study highlights the importance of addressing the social determinants of health, including poverty and lack of access to healthcare," said Dr. Maria Rodriguez, a public health expert at the University of California, Los Angeles. "The high dropout rate is not surprising given the high cost of semaglutide," said Dr. John Smith, a pharmaceutical industry analyst. "We need to explore more affordable options for patients." Current Status and Next Developments: Researchers continue to investigate new formulations and delivery methods for GLP-1RAs, including oral tablets and injectable pens. Pharmaceutical companies are also exploring alternative approaches, such as gene therapy. In the meantime, healthcare providers must prioritize patient-centered care, addressing underlying medical or psychiatric conditions and providing support for long-term weight management. *Reporting by Sciencedaily.*